20/20 Biolabs, Inc. - SIC # 8081 -

Ticker Exchange SIC # Website Latest Ticker
AIDX Nasdaq 8081 2020biolabs.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for 20/20 Biolabs, Inc.

20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock - Jul 23rd, 2026 6:31 am
20/20 BioLabs Highlights Investor Webinar Focused on OneTest™ for Medicare, Serial Biomarker Tracking, and Strong Q2 Revenue Growth - Jul 9th, 2026 2:01 pm
20/20 BioLabs Announces Monthly Investor Webinar Series to be Held on the First Wednesday of Each Month - Jun 22nd, 2026 2:45 pm
20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters - May 27th, 2026 6:31 am
20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand - May 22nd, 2026 6:31 am
20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress - May 20th, 2026 2:05 pm
Sidoti Events, LLC's May Micro-Cap Virtual Conference - May 20th, 2026 5:30 am
20/20 BioLabs to Attend Sidoti Micro-Cap Virtual Conference on May 20, 2026 - May 14th, 2026 6:31 am
20/20 BioLabs Exclusively Licenses PSA Velocity Algorithm from the University of South Carolina - May 12th, 2026 6:31 am
HEALWELL to Participate in Upcoming 2026 Bloom Burton & Co. Healthcare Investor Conference - Apr 13th, 2026 5:00 am
BIO-key International, 20/20 Biolabs, Society Pass, and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Apr 10th, 2026 8:00 am
20/20 BioLabs Selected by Evexia Diagnostics to Offer OneTest™ for Cancer Through Evexia Platform - Apr 7th, 2026 6:31 am
20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress - Mar 31st, 2026 2:57 pm
Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs’ OneTest ™ Multi-Cancer Early Detection Blood Test - Mar 27th, 2026 6:31 am
20/20 BioLabs Announces Exclusive U.S. License Agreement with ROKIT Healthcare to Integrate Advanced CKD Prediction Technology into Its Longevity Test Program - Mar 24th, 2026 6:31 am
How The Healwell AI (TSX:AIDX) Investment Story Is Shifting With Recut Targets And Growth Assumptions - Mar 22nd, 2026 8:05 am
HEALWELL AI Delivers Record Revenue and First Year of Positive Adjusted EBITDA as Global AI Platform Strategy Takes Hold - Mar 19th, 2026 5:00 am
20/20 BioLabs Highlights Advantages of its Patented Protein Biomarker Technology for Multi-Cancer Early Detection in Light of Recent Studies - Mar 12th, 2026 6:31 am
20/20 BioLabs Launches OneTest for Longevity Blood Test and Chronic Disease Risk Assessment and Management Solution Built with IBM AI Capabilities - Feb 25th, 2026 6:31 am
20/20 BioLabs to Host Virtual Investor Webinar on Thursday, February 26, 2026 at 2:00 p.m. Eastern Time - Feb 20th, 2026 6:31 am